Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis

Table 1

Summary of patient characteristics.

At baseline
Number of patients/eyes	11/22
Sex (male: female)	0 : 11
Age (yrs), mean (SD)	45.4 (19.1)
Location of lesion	Only ON 8 cases, ON + myelitis and encephalitis 3 cases
Antibodies	AQP4 antibody: 9 cases
	MOG antibody: 3 cases
	Double positive: 1 case
At the initiation of immunosuppressive therapy
Mean age, years (SD)	42.5 (19.7)
Mean number of ON attack episodes (SD)	1.7 (1.0)
Mean number of myelitis and encephalitis episodes (SD)	0.7 (1.4)
Median follow-up period before start of immunosuppressive therapy, years (first-third quartile)	1.8 (0.8–5.2)
Types of treatments (number of patients)
Only methylprednisolone	4
Methylprednisolone + plasma exchange	4
Methylprednisolone + intravenous immunoglobulin	2
Methylprednisolone + intravenous immunoglobulin + plasma exchange	1

SD: standard deviation, ON: optic neuritis, AQP4: anti-aquaporin4 antibody, MOG: anti-myelin oligodendrocyte glycoprotein MP: methylprednisolone, PE: plasma exchange, IVIg: intravenous immunoglobulin.